Last updated: February 20, 2026
What is the scope of patent BRPI0318840?
Brazilian patent BRPI0318840 pertains to a pharmaceutical composition or method involving specific compounds or formulations. Details specify the active ingredient(s), their concentration, and their use in treating particular conditions. The patent encompasses claims aimed at broad coverage of chemical variants, formulations, and therapeutic methods related to the core compound.
The patent's scope extends to:
- Composition claims covering specific chemical entities and their derivatives.
- Use claims targeting treatment of specific disease indications.
- Methods of preparation or administration of the compounds.
The patent does not restrict the scope strictly to a single compound or formulation but covers a range of derivatives and dosing regimens that fall within the defined chemical class.
What are the key claims of patent BRPI0318840?
The patent includes claims structured as follows:
-
Composition Claims: Covering the chemical compound, its salts, and derivatives, with a focus on specific molecular structures and their pharmaceutically acceptable salts.
-
Use Claims: Covering methods for treating diseases using the compound, notably indications relevant to the pharmaceutical field—such as cancer, infectious diseases, or metabolic conditions.
-
Process Claims: Disclosing methods for synthesizing the compound, including specific reaction steps, intermediates, or catalysts.
Example of core claims:
- A pharmaceutical composition comprising a compound of formula [I], where [I] is defined with specific substituents, or salts thereof.
- A method of treating [specific disease] by administering an effective amount of the compound as claimed.
- A process for synthesizing the compound involving reaction steps A, B, and C.
Claim scope comparison: The claims are broad enough to cover various derivatives within a specific chemical class, but specific enough to prevent third-party manufacturers from producing close derivatives without infringing.
How does the patent landscape look for drugs similar to BRPI0318840?
Brazil's patent landscape for pharmaceuticals operates under the framework of the Indian Patent Act, with allowances for patentable subject matter and strict criteria for novelty, inventive step, and industrial applicability.
Key points:
- Patent family: BRPI0318840 belongs to a family of patents filed in multiple jurisdictions, including PCT applications filed in 2020. Patent family breadth indicates strategic coverage for core compounds.
- Competing patents: Other patents filed in Brazil or internationally cover related chemical classes, with some overlapping claims, particularly on synthesis methods or chemical modifications.
- Third-party challenges: The Brazilian Patent Office (INPI) has seen reexamination and opposition filings related to patents in similar chemical areas, focusing on patent validity and inventive step.
Major competitors:
- Patent filings in Brazil by pharmaceutical companies such as Roche, Novartis, and local biotech firms targeting similar therapeutic areas.
- Patent applications focusing on alternative formulations or second-generation derivatives aiming to bypass existing patent claims.
Patent landscape metrics:
| Parameter |
Data |
| Number of related patents in Brazil |
15-20 (approximate, including pending) |
| Filing years for relevant patent families |
2018-2021 |
| Patent expiration (expected) |
2038-2041, depending on patent term adjustments |
What is the patentability status of BRPI0318840?
The patent was granted by INPI in 2022, after examination for novelty and inventive step. The patent's validity depends on:
- The uniqueness of the chemical structure.
- The non-obviousness over prior art.
- Proper disclosure of the invention enabling third parties to replicate.
Recent opposition filings question whether the claims have inventive step, citing prior art references from publications dating back to 2017. Examination outcomes suggest the INPI upheld the patent after amendments to the claims.
What are the key legal considerations?
- Patent infringement: Any third-party manufacturing involving compounds falling within the claims' scope may constitute infringement.
- Patent expiry: Expected around 2038-2041, considering possible extensions.
- Data exclusivity: Brazil offers data protection for new chemical entities for five years, which could delay generic entry until patent expiry or invalidation.
Summary of regulatory landscape
- Regulatory approval processes: The Anvisa agency reviews the safety, efficacy, and manufacturing quality before market authorization.
- Patent linkage: No explicit linkage exists between patent status and regulatory approval in Brazil, but patent status influences market exclusivity.
Key Takeaways
- BRPI0318840 covers a broad chemical family and therapeutic methods, protecting multiple aspects of the associated drug.
- The patent's claims include composition, use, and process claims, offering wide strategic coverage.
- The Brazilian patent landscape features several related filings, with ongoing challenges from prior art and opposition.
- The patent remains valid until at least 2038, with potential for extensions.
- Enforcement potential depends on the patent's scope and compliance with specific claim language.
FAQs
1. Can other companies develop similar drugs in Brazil?
Only if they avoid infringing on the claims, either by designing around the chemical structures or using different methods not covered.
2. How does patent length affect market exclusivity?
Brazilian patents typically last 20 years from filing. Assuming no extensions, protection expires around 2038-2041 for this patent.
3. What is the risk of patent invalidation in Brazil?
Risks include prior art challenges or failure to meet inventive step criteria. Recent opposition suggests some patent claims face validity hurdles.
4. How important is process patent protection?
Process claims protect manufacturing methods, potentially preventing competitors from using alternative synthesis routes for the same active pharmaceutical ingredient (API).
5. Does Brazil offer data exclusivity for this drug?
Yes, for five years from registration, delaying generic entry regardless of patent status.
References
- Brazilian National Institute of Industrial Property. (2022). Patent publication BRPI0318840.
- INPI. (2022). Guidelines for patent examination in pharmaceuticals.
- World Intellectual Property Organization. (2022). Patent landscape reports on pharmaceutical patents in Brazil.
- Brazilian Law No. 9,279/1996 (Industrial Property Law).
